SpringerLink
Log in

Clinico-Pathological Characteristics, Management, and Prognostic Factors of Patients with Uterine Carcinosarcoma: a Retrospective Analysis

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Uterine carcinosarcoma is a rare, highly aggressive, rapidly progressing neoplasm associated with a poor prognosis. It comprises 1–5% of all uterine malignancies but accounts for 16.4% of all deaths caused by uterine malignancies. There is a definite paucity of data available from the Indian subcontinent. Hence, we retrospectively conducted this study to analyze the clinical and pathological characteristics and outcomes of women with uterine carcinosarcoma in the past 10 years managed at the tertiary care center. This is a retrospective study of women with histologically proven uterine carcinosarcoma treated at a tertiary cancer center in South India between August 2009 and April 2019. Inpatient and outpatient records were reviewed; clinicopathological data were collected; and follow-up and survival data were ascertained. Over a period of 10 years, 20 patients were diagnosed with uterine carcinosarcoma. The majority of patients were postmenopausal (80%). Post-menopausal bleeding was the main presenting complaint in about 80% of patients. More than two-thirds of patients presented in the early stage (stage I, 55%; stage II, 20%). All patients underwent staging laparotomy. Patients with good performance status (85%) received adjuvant concurrent chemoradiotherapy and chemotherapy. At a median follow-up of 40 months, 7 (35%) patients were alive, out of which 6 are disease-free and 1 had a recurrence. The event-free survival at a median follow-up of 40 months was 40% and the overall survival was 48.5%. The outcome did not significantly differ based on the age, tumor histology (heterologous versus homologous), stage, and depth of myometrial invasion. Uterine carcinosarcoma, though rare, needs to be recognized as a distinct entity, and treated aggressively. Surgery is the cornerstone of therapy. Adjuvant concurrent chemoradiation and chemotherapy improve local control and may delay recurrence, but have shown little survival advantage. The optimal adjuvant treatment for this uncommon disease is yet to be established, highlighting the need for larger multicentric studies on this tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Spain)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schweizer W, Demopoulos R, Beller U, Dubin N (1990) Prognostic factors for malignant mixed Müllerian tumors of the uterus. Int J Gynecol Pathol 9:129–136

    Article  CAS  PubMed  Google Scholar 

  2. Bosquet JS, Terstriep SA, Cliby WA et al (2010) The impact of multi-modal therapy on survival for uterine carcinosarcomas. GynecologicOncology 116(3):419–423

    Article  Google Scholar 

  3. Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H (2005) Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96(3):630–634

    Article  CAS  PubMed  Google Scholar 

  4. Spanos WJ Jr, Peters LJ, Oswald MJ (1986) Patterns of recurrence in malignant mixed müllerian tumor of the uterus. Cancer 57:155–159

    Article  PubMed  Google Scholar 

  5. D’Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116:131–139

    Article  PubMed  Google Scholar 

  6. Leath CA, Numnum TM, Kendrick JE, Frederick PJ, Rocconi RP, Conner MG et al (2009) Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer 19:888–891

    Article  PubMed  Google Scholar 

  7. Gokce ZK, Turan T, Karalok A, Tasci T, Ureyen I, Ozkaya E et al (2015) Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer 25:279–287

    Article  PubMed  Google Scholar 

  8. Curtin JP, Blessing JA, Soper JT, DeGeest K (2001) Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 83:268–270

    Article  CAS  PubMed  Google Scholar 

  9. Odei B, Boothe D, Suneja G, Werner TL, Gaffney DK (2018) Chemoradiation versus chemotherapy in uterine carcinosarcoma: patterns of care and impact on overall survival. Am J Clin Oncol 41:784–791

    Article  PubMed  Google Scholar 

  10. Rauh-Hain JA, Starbuck KD, Meyer LA, Clemmer J, Schorge JO, Lu KH et al (2015) Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis. Gynecol Oncol 139:84–89

    Article  PubMed  Google Scholar 

  11. Gadduci A, Cosio S, Romanini A, Genazzani AR (2008) The management of patients with uterine sarcoma: a debated critical challenge. Crit Rev Oncol Hematol 65:129–142

    Article  Google Scholar 

  12. Abdulfatah E, Lordello L, Khurram M, Van de Vijver K, Alosh B, Bandyopadhyay S, Oliva E, Ali-Fehmi R (2018) Predictive histologic factors in carcinosarcomas of the uterus: a multiinstitutional study. Int J Gynecological Pathol 38:1. https://doi.org/10.1097/PGP.0000000000000497

    Article  Google Scholar 

  13. Nielsen SN, Podratz KC, Scheithauer BW, O’Brien PC (1989) Clinicopatho-logic analysis of uterine malignant mixed Mullerian tumors. GynecolOncol 34:372–378

    CAS  Google Scholar 

  14. Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson EM, Yandissemindell RB (1989) Mixed Mullerian tumor of the uterus: a clinicopathologic study. Obstet Gynecol 74:388–392

    CAS  PubMed  Google Scholar 

  15. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ et al (2007) A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:177–85

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H, Gynecologic Oncology Group (2005) Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96:630–4

    Article  CAS  PubMed  Google Scholar 

  17. Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM et al (2017) Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol 145:78–87

    Article  PubMed  PubMed Central  Google Scholar 

  18. Guttmann DM, Li H, Sevak P, Grover S, Jacobson G, Feldman A et al (2016) The impact of adjuvant therapy on survival and recurrence patterns in women with early- stage uterine carcinosarcoma: a multi-institutional study. Int J Gynecol Cancer 26:141–148

    Article  PubMed  Google Scholar 

  19. Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH (2007) Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 107(3):513–7. https://doi.org/10.1016/j.ygyno.2007.08.060

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G et al (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 79:147–153

    Article  CAS  PubMed  Google Scholar 

  21. Anupama R, Kuriakose S, Vijaykumar DK, Pavithran K, Jojo A, Indu RN et al (2013) Carcinosarcoma of the uterus-a single institution retrospective analysis of the management and outcome and a brief review of literature. Indian J Surg Oncol 4:222–228

    Article  PubMed  PubMed Central  Google Scholar 

  22. Powell MA, Filiaci VL, Rose PG et al (2010) Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of theuterus: a Gynecologic Oncology Group study. J Clin Oncol 28:2727–2731

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cantrell LA, Havrilesky L, Moore DT et al (2012) A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol 127:22–26

    Article  PubMed  Google Scholar 

  24. Callister M, Ramondetta LM, Jhingran A et al (2004) Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 58:786–796

    Article  PubMed  Google Scholar 

  25. Chi DS, Mychalczak B, Saigo PE et al (1997) The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 65:493–498

    Article  CAS  PubMed  Google Scholar 

  26. Nemani D, Mitra N, Guo M, Lin L (2008) Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 111:82–88

    Article  PubMed  Google Scholar 

  27. Galaal K, van der Heijden E, Godfrey K et al (2013) Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2:CD006812

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Choithram Hospital and Research Centre, Indore, India

    Abhilasha Goyal

  2. Department of Gynaec-Oncology, Kidwai Cancer Institute Bengaluru, Bengaluru, India

    S. K. Rajshekar, Shobha Krishnappa, Praveen S. Rathod, Pallavi V. Reddihalli, U. D. Bafna, Yamini Kansal, Sravanthi Nuthalapati & Amarinder Singh

Authors
  1. Abhilasha Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. K. Rajshekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shobha Krishnappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Praveen S. Rathod
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pallavi V. Reddihalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U. D. Bafna
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yamini Kansal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sravanthi Nuthalapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amarinder Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. K. Rajshekar.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goyal, A., Rajshekar, S.K., Krishnappa, S. et al. Clinico-Pathological Characteristics, Management, and Prognostic Factors of Patients with Uterine Carcinosarcoma: a Retrospective Analysis. Indian J Surg Oncol 14, 466–472 (2023). https://doi.org/10.1007/s13193-022-01563-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-022-01563-1

Keywords

Search

Navigation